Anavex Life Sciences Corp. (AVXL)

3,8500 +0,0900 (+2,39%) Börsenschluss: 04:00PM EDT

Anavex Life Sciences Corp.

630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939
https://www.anavex.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 40

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.	President, CEO, Secretary & Director	828,25k	3,2M	1966
Ms. Sandra Boenisch CPA, CGA	Principal Financial Officer & Treasurer	194,36k	N/A	1981
Mr. Stephan Toutain M.B.A., M.S.	Senior VP of Operations & COO	N/A	N/A	1966
Dr. Walter E. Kaufmann M.D.	Chief Scientific Officer	N/A	N/A	N/A
Clint Tomlinson	VP of Corporate	N/A	N/A	N/A
Dr. Adebayo Laniyonu Ph.D.	Senior Vice President of Nonclinical Development	N/A	N/A	N/A
Dr. Edward R Hammond M.D., M.P.H., Ph.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Kun Jin Ph.D.	Head of Biostatistics	N/A	N/A	N/A
Mr. David Goldberger R.Ph.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Corporate Governance

Anavex Life Sciences Corp.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 7, Vorstand: 3, Shareholderrechte: 1, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.